Canadian approval for Thoratec Laboratories:
This article was originally published in Clinica
Thoratec Laboratories has received Canadian approval for its TLC-II portable VAD driver. The device is used to power the Thoratec VAD system which pumps blood to the body in heart failure patients awaiting transplantation. Its small size and light weight means that patients are mobile and independent after they leave the intensive care unit. The Pleasanton, California-based company said it is the only portable cardiac assist device which is capable of treating patients by providing right, left or biventricular support. The company has submitted an investigational device exemption to begin US clinical trials of the device.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.